Barclays raised the firm’s price target on Eli Lilly to $913 from $810 and keeps an Overweight rating on the shares post the Q1 report. The company’s guidance addressed key near-term concerns and the stock’s catalyst backdrop is turning more favorable, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY Earnings: Eli Lilly Gains on Strong Q1 Earnings Beat
- Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
- Eli Lilly And Company (LLY) Q1 Earnings Cheat Sheet
